July 26, 2012
/PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that it received a notice of issuance for patent number 12/710,097 titled: "Transplantation of Human Neural Cells for Treatment of Neurodegenerative Conditions." This patent covers both the culturing of central nervous system cells as well as their transplantation into spinal cord tissue to treat neurodegenerative conditions, including amytrophic lateral sclerosis (ALS or
's disease). Neuralstem is currently conducting a Phase I safety trial of its human spinal cord stem cells in the treatment of ALS.
"This is a major addition to our patent estate," said Neuralstem Chairman & Chief Scientific Officer,
, PhD. "This patent includes claims covering processes for dissociating our neural stem cells from central nervous system tissue; culturing the cells; expanding the cells in vitro and transplanting the neural stem cells into the spinal cord of a patient to treat a wide array of neurodegenerative conditions including, amyotrophic lateral sclerosis (ALS)."
"We are pleased to have this new patent issued, which will expire in Q1 2030," said Neuralstem President & CEO,
. "We have currently transplanted 17 patients in our ALS trial and we have been encouraged by the results so far. We are focused on this program as our first potential transplantation product. We believe that having this specific patent coverage as well as this patent life into 2030 is reflective of the value we are creating in our cell therapy programs."
Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as
's disease, and has been awarded orphan status designation by the FDA.
In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.